Biocon has received the Certificate of GMP compliance from EMA for its Biologics Drug Product (DP) as well as Drug Substance (DS) facilities at Biocon Park, Bengaluru. These facilities, used for the manufacture of Biocon's portfolio of biosimilars, were inspected by the European agency in March 2019. This was a surveillance inspection of Biocon’s existing DP and OS facilities and a pre-approval inspection of its additional DP manufacturing line.This certification would enable Biocon to continue addressing the growing needs of patients in the EU markets and enhance its access for high quality biosimilars.

Biocon has received the Certificate of GMP compliance from EMA for its Biologics Drug Product (DP) as well as Drug Substance (DS) facilities at Biocon Park, Bengaluru.